What is Haemonetics's medsurg — R&D?

Haemonetics (HAE) reported medsurg — R&D of $9.82M in Q2 2026.

What does medsurg — R&D mean?

Represents the investment made by the MedSurg segment into the innovation, design, and clinical validation of new medical products and solutions. High levels of R&D spending indicate a commitment to long-term growth and maintaining a competitive technological edge.

Haemonetics (HAE) MedSurg — R&D

Screener

Other segment segments

Apheresis

$6.38M—

Similar metrics at other companies

INSMARIKAYCE external R&D expenses — R&D

$6.23M-43.4%

INSMBrensocatib external R&D expenses — R&D

$13.83M-58.8%

INSMTPIP external R&D expenses — R&D

$38.94M+88.6%

INSMOther external R&D expenses — R&D

$48.84M+71.7%

MUAEBU — R&D

$109M+0.9%

MUCDBU — R&D

$358M+76.4%

Other financials

Income statement

See full

Revenue$339.4M+5.6%

Gross profit$202.8M+5.5%

Operating income$57.5M+6.7%

Net income$33.0M-3.0%

EPS (diluted)$0.72+2.9%

Balance sheet

See full

Cash & equivalents$223.4M-23.7%

Total debt$1.2B-4.1%

Total equity$837.1M-5.1%

Total assets$2.4B-3.9%

Cash flow

See full

Operating cash flow$52.3M+201%

CapEx$7.9M+111%

Free cash flow$44.4M+226%

Valuation

See full

Market cap$3.87B+6.3%

Enterprise value$4.82B+5.4%

P/E25.7×-10.5×

P/S2.9×+0.2×

Profitability

See full

Gross margin59%+2.1pp

Operating margin19%+5.9pp

Net margin13.3%+3.8pp

FCF margin21.5%+7.5pp

Returns & leverage

See full

Return on equity19.3%+5.2pp

Debt / equity1.4×0.0×

Current ratio3.1×+1.4×

Where this comes from

Reported directly by Haemonetics in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The source filing: Haemonetics’s 10-Q, filed August 6, 2026.

Filed: Aug 6, 2026, 6:09 AM EDT
Fiscal quarter: Q1 FY2027
Calendar quarter: Q2 2026
Accession: 0000313143-26-000120

Line item	Three Months Ended / June 27, 2026	Three Months Ended / June 28, 2025
MedSurg
Cost of goods sold	$50,368	$50,216
Selling, general and administrative	65,160	62,323
Research and development	9,820	8,742
MedSurg operating income	$22,714	$18,377
Corporate and unallocated expenses
Amortization of acquired assets	$(10,204)	$(13,828)
Integration and transaction costs	(2,719)	(2,682)

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Haemonetics's medsurg — R&D?: Haemonetics (HAE) reported medsurg — R&D of $9.82M in Q2 2026.
What does medsurg — R&D mean?: Represents the investment made by the MedSurg segment into the innovation, design, and clinical validation of new medical products and solutions. High levels of R&D spending indicate a commitment to long-term growth and maintaining a competitive technological edge.